Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

Medically reviewed by Brendan Camp, MD Psoriasis affects about 3% of all adults in the United States, and Asian Americans ...

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

Lucknow: King George's Medical University (KGMU) will soon offer advanced treatment options for conditions such as vitiligo (leukoderma) and psoriasis.

The "Plaque Psoriasis Market by Treatment, by Route of Administration, by End-user, and by Region" report has been added to ...

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

psoriasis drugs market is expected to expand significantly, growing from an estimated USD 19.65 billion in 2024 ...

A new study published in the Archives of Dermatological Research found that patients with psoriasis who were receiving ...

Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies ...